CRISPR Therapeutics AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRSP | NTLA | SANA | EDIT | SCTX | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 5.02B | 1.72B | 766.36M | 417.74M | 317.67M | 1.81B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -14.4 | -4.8 | -4.6 | -3.6 | -4.6 | -23.0 |
| Price/book | 3.0 | 2.4 | 5.0 | 4.0 | -0.3 | 85.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −8.54% | −0.08% | −36.79% | +1.12% | −11.54% | +29.08% |
| Today | +3.57% | +3.79% | +4.92% | +4.62% | +3.58% | −3.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CRSP news ›Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital
In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 36.64% success…
Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crispr Therapeutics AG (CRSP) and Faeth Therapeutics (FTH) with bullish sentiments. Crispr Therapeutics AG (CRSP) In a report released today,…
Dr. Judith Hartmann to become new Chief Financial Officer of Bayer AG
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold in the United States absent registration…
How a CRISPR sickle cell therapy moved from lab to clinical trial
A UCLA-led team has described how they advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial. The study was published…
More from 1 other outlet
New CRISPR proteins expand editing access to heart disease genes
Rice professor evolves new Cas9 enzymes image: Sequence Display-enabled deep learning helps improve SlugCas9, a compact CRISPR tool, to edit challenging DNA sites in APOC3 and PCSK9, two genes linked to coronary heart disease risk. view…
More from 1 other outlet
In the US, UCLA team establishes CRISPR therapy production for trial — News-Medical
In the United States, a team at the University of California, Los Angeles developed a reproducible process for manufacturing an experimental CRISPR therapy for sickle cell disease at the scale required for a clinical trial. The approach…
Cryo-EM reveals how a retrotransposon and CRISPR–Cas9 team up to insert genes
Cryo-electron microscopy structures of the zebra finch R2 retrotransposon, alone and bound to Cas9, reveal how target-primed reverse transcription initiates and guided the engineering of an enhanced STITCHR gene-integration system. Subject…
CRISPR Therapeutics (NASDAQ:CRSP) Stock Gets Price Target Boost from Citigroup
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) had its target price boosted by stock analysts at Citigroup from $88.00 to $90.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock.…
CRISPR Therapeutics AG $CRSP Stock Sold by Sumitomo Mitsui Trust Group Inc.
Check Out Our Latest Research Report on CRISPR Therapeutics Here are the key news stories impacting CRISPR Therapeutics this week: Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex…
Head-To-Head Comparison: CRISPR Therapeutics (NASDAQ:CRSP) vs. Rallybio (NASDAQ:RLYB)
Posted by Tristan Rich on Nov 4th, 2026 CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Rallybio (NASDAQ:RLYB – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com12
- marketscreener.com11
- stocktitan.net9
- fool.com7
- themarketsdaily.com6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 105 articles, not a forecast.